The frequencies of antidiabetic drug use are shown in Table 2
Anyone presenting the combination as clinically proven is going beyond the evidence
Efficacy comparison by clinical trial data The most relevant head-to-head data comes from the SURPASS-2 trial (tirzepatide vs semaglutide 1 mg for type 2 diabetes) and the SURMOUNT-5 trial (tirzepatide vs semaglutide 2.4 mg for obesity)
All the participants underwent a series of tests to measure their weight, blood glucose, plasma insulin and glucagon levels
Investigation of the mechanisms underlying the beneficial metabolic effects of multi-agonist therapies, conducted in PWA mice, as a genuine model for the metabolic alterations of PCOS 36 , revealed a predominant action in terms of suppression of food intake, with negligible effects in terms of energy expenditure, thermogenic function or locomotor activity
Our program has been prescribing GLP-1 receptor agonist medications for many years and found them to be a valuable, effective treatment tool that can help position patients for success and a healthier future